(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
09 November 2017 (09.11.2017)

WIPO | PCT

(10) International Publication Number
WO 2017/192711 A8

(51) International Patent Classification:
A61K 38/17 (2006.01) *C07K 16/28* (2006.01)
C07K 14/775 (2006.01)

(21) International Application Number:
PCT/US2017/030826

(22) International Filing Date:
03 May 2017 (03.05.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/331,055 03 May 2016 (03.05.2016) US
62/402,270 30 September 2016 (30.09.2016) US

(71) Applicants: **UNIVERSITY OF SOUTH FLORIDA** [US/US]; 3802 Spectrum Blvd., Suite 100, Tampa, FL 33612 (US). **UNITED STATES DEPARTMENT OF VETERANS AFFAIRS** [US/US]; 810 Vermont Avenue NW, Washington, DC 20420 (US).

(72) Inventors: **SAWMILLER, Darrell**; 22902 Hawk Hill Loop, Land O Lakes, FL 34639 (US). **HOU, Huayan**; 19249 Wood Sage Dr., Tampa, FL 33647 (US). **TAN, Jun**; 10260 Estuary Dr., Tampa, FL 33647 (US).

(74) Agent: **MILLER, Carin R.**; Thomas I Horstemeyer LLP, 3200 Windy Hill Rd SE, Suite 1600E, Atlanta, GA 30339 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR,

(54) Title: COMPOSITIONS AND METHODS OF MODULATING ABETA PROTEIN




FIG. 1

(57) Abstract: Provided herein are compounds, compositions, formulations that can modulate binding of an ApoE protein to an ApoE receptor. Also provided herein are screening assays that can be capable of identifying compounds that can modulate binding of an ApoE protein to an ApoE receptor. Also provided herein are recombinant polypeptides that are capable of inhibiting binding of ApoE protein to an ApoE receptor. Also provided herein are transformed cells transgenic animals that can express a recombinant ApoE low-density lipoprotein receptor binding domain. Also provided herein are methods of administering a compound, compositions, or formulation thereof to a subject in need thereof, where the subject in need thereof suffers from or is at risk for a disease or disorder where abnormal ApoE binding to an ApoE receptor is at least part of the pathology of the disease or disorder.

WO 2017/192711 A8

[Continued on next page]

KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:
21 March 2019 (21.03.2019)

(15) Information about Correction:
see Notice of 21 March 2019 (21.03.2019)